Bridge Biotherapeutics (XKRX:288330) Accounts Payable & Accrued Expense : ₩2,191.47 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Bridge Biotherapeutics Accounts Payable & Accrued Expense?

Bridge Biotherapeutics's quarterly accounts payable & accrued expense declined from Sep. 2024 (₩2,050.26 Mil) to Dec. 2024 (₩1,668.91 Mil) but then increased from Dec. 2024 (₩1,668.91 Mil) to Mar. 2025 (₩2,191.47 Mil).

Bridge Biotherapeutics's annual accounts payable & accrued expense increased from Dec. 2022 (₩2,102.68 Mil) to Dec. 2023 (₩5,182.57 Mil) but then declined from Dec. 2023 (₩5,182.57 Mil) to Dec. 2024 (₩1,668.91 Mil).

Bridge Biotherapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Bridge Biotherapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bridge Biotherapeutics Accounts Payable & Accrued Expense Chart

Bridge Biotherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

659.66

2,125.66

2,102.68

5,182.57

1,668.91

Bridge Biotherapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2,628.77	1,958.58	2,050.26	1,668.91	2,191.47

Bridge Biotherapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Bridge Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bridge Biotherapeutics Inc (XKRX:288330) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

58, Pangyo - ro, Gyeonggi No. 303, 255 beongil Seas Tower in Bundang Pangyo, Seongnam-si, KOR, 13486

Website

http://www.bridgebiorx.com

Bridge Biotherapeutics Inc is a drug research and development company. It operates in the pharmaceutical and bio industry. The company has two pipeline clinical-stage products namely, BBT-401 and BBT-877.

Bridge Biotherapeutics Headlines

No Headlines